Sign in

    Neuropace Inc (NPCE)

    Q1 2024 Earnings Summary

    Reported on Apr 3, 2025 (After Market Close)
    Pre-Earnings Price$12.60Last close (May 8, 2024)
    Post-Earnings Price$12.42Open (May 9, 2024)
    Price Change
    $-0.18(-1.43%)

    What went well

    • Robust Pipeline and Prescriber Expansion: The company reported significant increases in new prescriber numbers, driven by both greater adoption within existing centers and new site additions, indicating a strong and growing clinical pipeline.
    • Innovative Product Strategy and Expanded Indications: The hybrid approach combining RNS with resection therapy—with ongoing studies like NAUTILUS in the follow‐up phase—highlights potential for market expansion, including a first FDA-approved indication for generalized epilepsy.
    • Growth Potential in DIXI Product Line: Management expects continued growth in the DIXI product segment, driven by increasing use of diagnostic electrodes in comprehensive epilepsy centers, further complementing the overall RNS strategy.

    What went wrong

    • Declining Replacement Revenue: The Q&A noted that replacement implant revenue is trending downward and is expected to remain a headwind—especially in the first half of the year—even though it only currently represents about 4% of total revenue.
    • High Operating Expenses and Cash Burn: Despite revenue beat in Q1, the company reported a net loss and maintained a cash burn of $7.6 million, highlighting ongoing challenges with operating leverage and expense management.
    • Seasonality and Delayed Ramp-up: The discussion on cadence indicated potential seasonal slowdowns (e.g., summer holidays and Q4 events) and uncertainties in new prescriber ramp-up, which may delay revenue contributions from recent commercial expansions.

    Q&A Summary

    1. Guidance Assumptions
      Q: What key assumptions shape current guidance?
      A: Management based guidance on Q1's strong RNS and DIXI performance, while factoring in moderate headwinds from replacement revenue in H1 and anticipated field expansion later in the year.

    2. Gross Margin
      Q: Why not raise margin guidance after a beat?
      A: They explained that improved margins were driven by higher unit sales and a biotech collaboration, though partially offset by lower margins on DIXI products.

    3. Replacement Revenue
      Q: Will headwinds for replacement revenue ease?
      A: Management expects replacement revenue reduction to be more pronounced in the first half, with moderation in the second half as the trend stabilizes.

    4. Quarterly Cadence
      Q: What revenue cadence should investors expect?
      A: They noted that while they don’t guide quarterly, seasonal factors—such as summer slowdowns and holiday impacts around Q4—play a role in the cadence.

    5. Biotech Milestone
      Q: Was a milestone payment received under the biotech deal?
      A: Management confirmed milestone payments are part of a $3.7M total contract over nine quarters, though specifics were not detailed.

    6. Implant Revenue Timing
      Q: When can implant revenue be expected?
      A: They anticipate implant-related revenue to pick up chiefly in the second half as pilot programs and referrals mature.

    7. DIXI Growth
      Q: What is the long-term outlook for DIXI?
      A: Management expects steady growth in DIXI driven by increased diagnostic use in epilepsy centers and a stronger foothold in the overall portfolio.

    8. New Prescriber Sources
      Q: Where are new prescribers coming from?
      A: New prescribers are emerging from both existing centers expanding use and fresh accounts adopting the technology, reflecting deeper market penetration.

    9. Prescriber Training
      Q: How quickly do new prescribers become effective?
      A: A structured and reproducible training program is in place to ensure that new users gradually ramp up to perform at average levels.

    10. Procedure Pipeline
      Q: What’s the state of the patient and procedure pipeline?
      A: There is a consistently robust pipeline with normalized diagnostic and referral volumes across centers, indicating steady future growth.

    11. Project CARE Metrics
      Q: How will Project CARE progress be tracked?
      A: Progress is measured through a detailed pipeline—from initial contacts and education to patient referrals and eventual implants—ensuring transparent monitoring of the program.

    12. R&D Focus
      Q: What areas are current R&D investments targeting?
      A: Investments are focused on clinical follow-up studies like NAUTILUS, enhancements in AI-driven analytics, and broader product development initiatives.

    13. Hybrid Use Case
      Q: Are hybrid approaches with surgery emerging?
      A: Yes, management observed instances where RNS is used either prior to or in combination with resection surgery, aligning with a modern, integrated treatment approach.

    Related Publications